138 related articles for article (PubMed ID: 25116401)
1. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
Mundhenke C; Weigel MT; Sturner KH; Roesel F; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Hilpert F; Jonat W; Maass N
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1397-405. PubMed ID: 18465140
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
Teoh D; Ayeni TA; Rubatt JM; Adams DJ; Grace L; Starr MD; Barry WT; Berchuck A; Murphy SK; Secord AA
Gynecol Oncol; 2011 Apr; 121(1):187-92. PubMed ID: 21208651
[TBL] [Abstract][Full Text] [Related]
4. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
[TBL] [Abstract][Full Text] [Related]
5. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
6. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors.
Chu S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2008 Jan; 108(1):182-90. PubMed ID: 18028988
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells
Kuittinen T; Rovio P; Luukkaala T; Laurila M; Grénman S; Kallioniemi A; Mäenpää J
Anticancer Res; 2020 Jun; 40(6):3129-3138. PubMed ID: 32487607
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
[TBL] [Abstract][Full Text] [Related]
9. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
[TBL] [Abstract][Full Text] [Related]
10. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
Stamelos VA; Robinson E; Redman CW; Richardson A
Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/ß expression in squamous cell carcinoma of the head and neck in vitro.
Schultz JD; Rotunno S; Riedel F; Anders C; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Int J Oncol; 2011 Apr; 38(4):1001-12. PubMed ID: 21249316
[TBL] [Abstract][Full Text] [Related]
12. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
13. In Ovarian Cancer Multicellular Spheroids, Platelet Releasate Promotes Growth, Expansion of ALDH+ and CD133+ Cancer Stem Cells, and Protection against the Cytotoxic Effects of Cisplatin, Carboplatin and Paclitaxel.
Casagrande N; Borghese C; Agostini F; Durante C; Mazzucato M; Colombatti A; Aldinucci D
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809553
[TBL] [Abstract][Full Text] [Related]
14. AS602801, an Anticancer Stem Cell Candidate Drug, Reduces Survivin Expression and Sensitizes A2780 Ovarian Cancer Stem Cells to Carboplatin and Paclitaxel.
Yamamoto M; Suzuki S; Togashi K; Sanomachi T; Seino S; Kitanaka C; Okada M
Anticancer Res; 2018 Dec; 38(12):6699-6706. PubMed ID: 30504379
[TBL] [Abstract][Full Text] [Related]
15. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
[TBL] [Abstract][Full Text] [Related]
16. Metformin and epithelial ovarian cancer therapeutics.
Patel S; Kumar L; Singh N
Cell Oncol (Dordr); 2015 Oct; 38(5):365-75. PubMed ID: 26266765
[TBL] [Abstract][Full Text] [Related]
17. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
[TBL] [Abstract][Full Text] [Related]
18. Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.
Beltran PJ; Calzone FJ; Mitchell P; Chung YA; Cajulis E; Moody G; Belmontes B; Li CM; Vonderfecht S; Velculescu VE; Yang G; Qi J; Slamon DJ; Konecny GE
Clin Cancer Res; 2014 Jun; 20(11):2947-58. PubMed ID: 24727326
[TBL] [Abstract][Full Text] [Related]
19. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
20. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]